Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation.
Myint KZ, Balasubramanian B, Venkatraman S, Phimsen S, Sripramote S, Jantra J, Choeiphuk C, Mingphruedhi S, Muangkaew P, Rungsakulkij N, Tangtawee P, Suragul W, Farquharson WV, Wongprasert K, Chutipongtanate S, Sanvarinda P, Ponpuak M, Poungvarin N, Janvilisri T, Suthiphongchai T, Yacqub-Usman K, Grabowska AM, Bates DO, Tohtong R.
Myint KZ, et al.
Pharmaceuticals (Basel). 2024 Feb 2;17(2):197. doi: 10.3390/ph17020197.
Pharmaceuticals (Basel). 2024.
PMID: 38399413
Free PMC article.
Additionally, spheroid and xenograft models were employed to investigate the efficacy of ceritinib in vivo. Our study revealed that ceritinib effectively killed CCA cells at clinically relevant plasma concentrations, irrespective of ALK expression or mutation status. ...
Additionally, spheroid and xenograft models were employed to investigate the efficacy of ceritinib in vivo. Our study revealed that c …